Skip to main content
. 2010 Jan;42(1):113–119. doi: 10.1016/j.biocel.2009.09.018

Fig. 3.

Fig. 3

IL-1 activates JNK activity in Hep3B cells. (A) The cells were treated with IL-1 (100 U/ml) for the indicated period of time and whole cell extracts were subjected to western blot analysis using antiserum against phospho- and total-JNK. (B and C) The cells were treated in the absence or the presence of IL-1 (100 U/ml) for the indicated period of time (panel B), or pre-treated for 1 h with the DMSO vehicle control or the indicated concentration of curcumin (Cur), SP600125 or apigenin (Api) and then incubated for 15 min in the absence or the presence of this cytokine (− and +, respectively) (panel C). Whole cell extracts were subjected to the JNK kinase assay followed by western blot analysis with antiserum against phospho-c-Jun. Western blots probed with the β-actin antibody were used as a control for the amount of proteins in the extracts. The results shown are representative of two (A) to three (B–C) independent experiments.